Abstract
Bronchodilating effects produced by increasing intravenously administered doses of enprofylline and theophylline compared to placebo were evaluated in 20 asthmatic outpatients. Three mean plasma plateaux of enprofylline of 1.5, 2.9 and 4.0 micrograms/ml produced a mean increase in forced expiratory volume in the first second (FEV1.0) as a percentage of baseline, of 12.8%, 18.8% and 30.1%, respectively. Comparable plasma plateaux of theophylline i.e. 5.5, 10.8 and 15.2 micrograms/ml produced a mean increase of FEV1.0 in percent of basal values of 12.4%, 21.6% and 28.2%, respectively. Enprofylline at plasma concentrations above 2.9 micrograms/ml induced more headache and slightly more nausea than theophylline and placebo. Theophylline infusion produced more tremor (finger oscillation) than enprofylline and placebo. Intravenously administered enprofylline produces bronchodilation comparable to theophylline in a mean dose ratio of 3.8.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Andersson K. E., Johannesson N., Karlberg B., Persson C. G. Increase in plasma free fatty acids and natriuresis by xanthines may reflect adenosine antagonism. Eur J Clin Pharmacol. 1984;26(1):33–38. doi: 10.1007/BF00546705. [DOI] [PubMed] [Google Scholar]
- Borgå O., Andersson K. E., Edholm L. E., Fagerström P. O., Lunell E., Persson C. G. Enprofylline kinetics in healthy subjects after single doses. Clin Pharmacol Ther. 1983 Dec;34(6):799–804. doi: 10.1038/clpt.1983.252. [DOI] [PubMed] [Google Scholar]
- Edholm L. E. Specific methods for theophylline assay in biological samples. Eur J Respir Dis Suppl. 1980;109:45–53. [PubMed] [Google Scholar]
- Laursen L. C., Johannesson N., Dirksen A., Djurup R., Munch E. P., Taudorf E., Weeke B. Enprofylline--effects of a new bronchodilating xanthine derivative in asthmatic patients. Allergy. 1983 Jan;38(1):75–79. doi: 10.1111/j.1398-9995.1983.tb00859.x. [DOI] [PubMed] [Google Scholar]
- Laursen L. C., Johannesson N., Fagerström P. O., Weeke B. Intravenous administration of enprofylline to asthmatic patients. Eur J Clin Pharmacol. 1983;24(3):323–327. doi: 10.1007/BF00610048. [DOI] [PubMed] [Google Scholar]
- Lunell E., Svedmyr N., Andersson K. E., Persson C. G. A novel bronchodilator xanthine apparently without adenosine receptor antagonism and tremorogenic effect. Eur J Respir Dis. 1983 Jul;64(5):333–339. [PubMed] [Google Scholar]
- Lunell E., Svedmyr N., Andersson K. E., Persson C. G. Effects of enprofylline, a xanthine lacking adenosine receptor antagonism, in patients with chronic obstructive lung disease. Eur J Clin Pharmacol. 1982;22(5):395–402. doi: 10.1007/BF00542541. [DOI] [PubMed] [Google Scholar]
- Persson C. G., Erjefält I., Karlsson J. A. Adenosine antagonism, a less desirable characteristic of xanthine asthma drugs? Acta Pharmacol Toxicol (Copenh) 1981 Oct;49(4):317–320. doi: 10.1111/j.1600-0773.1981.tb00913.x. [DOI] [PubMed] [Google Scholar]
- Persson C. G., Kjellin G. Enprofylline, a principally new antiasthmatic xanthine. Acta Pharmacol Toxicol (Copenh) 1981 Oct;49(4):313–316. doi: 10.1111/j.1600-0773.1981.tb00912.x. [DOI] [PubMed] [Google Scholar]
- Taudorf E., Bundgaard A., Fagerström P. O., Weeke E., Weeke B. Terbutaline depot tablets in asthma. A clinical evaluation. Allergy. 1981 Oct;36(7):495–500. doi: 10.1111/j.1398-9995.1981.tb01861.x. [DOI] [PubMed] [Google Scholar]